Shanghai Henlius Biotech, Inc.
2696
Classificação em ações
#4242
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Preço da ação
$6.84
Valor de mercado
$3.73B
Variação (1 dia)
2.29%
Variação (1 ano)
-27.54%
País
CN
Negociar Shanghai Henlius Biotech, Inc. (2696)
Categoria
Healthcare
Número de ações em circulação para Shanghai Henlius Biotech, Inc. (2696)
Número de ações em circulação em June 2026: 544.86M
De acordo com os últimos relatórios financeiros e o preço das ações da Shanghai Henlius Biotech, Inc., o número atual de ações em circulação é 544.86M. No final de December 2023, a empresa tinha 546.02M ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Shanghai Henlius Biotech, Inc. (2696) de 2017 a 2026
Ações em circulação no final de cada ano
| Ano | Ações em circulação | Alterar |
|---|---|---|
| 2026 (TTM) | 544.86M | 0.25% |
| 2024 | 543.50M | -0.46% |
| 2023 | 546.02M | 0.74% |
| 2022 | 542.02M | 0.80% |
| 2021 | 537.73M | 1.75% |
| 2020 | 528.48M | 6.30% |
| 2019 | 497.16M | -4.53% |
| 2018 | 520.74M | -3.41% |
| 2017 | 539.13M | 0.00% |
Ações em circulação de empresas semelhantes ou concorrentes
| Empresa | Ações em circulação | Diferença | País |
|---|---|---|---|
| 253.90M | -53.40% |
US
|
|
| 396.00M | -27.32% |
US
|
|
| 478.91M | -12.10% |
AU
|
|
| 62.19M | -88.59% |
NL
|
|
| - | - |
CH
|
